The present method will enable the researcher to distinguish whether the adverse drug event is due to; the patient taking too much drug, drug interactions, genomic, proteomic, phenotypic, or other factors unrelated to the drug per se. [0317] It is a further object of the present invention that by analyzing the patient monitoring, genomic, proteomic, and physiologic data, one will be able to predic